{"analyses":[{"ciLowerLimit":"0.536","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.752","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.635","statisticalComment":"Adjusted for stratification factors: geographic region, time-to-progression from start of first-line therapy and disease measurability.","statisticalMethod":"Stratified Log Rank Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"5.3","value":"4.4"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"3.0","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"335"}],"units":"Participants"}],"description":"PFS was measured from date of randomization to first radiographically documented progressive disease (PD) or death due to any cause. PD defined using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Participants who had no baseline or post baseline radiological tumor assessment were censored at date of randomization. Participants who had no tumor progression or death within 2 scan intervals following the last assessment were censored at the date of last radiographic tumor assessment. Participants who began new anticancer treatment and had no tumor progression were censored at date of assessment prior to initiation of new therapy. Participants lost to follow-up or withdrew consent were censored at the date of their last assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"OG001","title":"Placebo Plus Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"All participants according to the treatment group to which they were randomized. Participants censored: Ramucirumab (IMC-1211B) plus Paclitaxel =51, Placebo plus Paclitaxel =39.","reportingStatus":"POSTED","timeFrame":"Randomization up to 22.2 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}